<DOC>
	<DOCNO>NCT01908205</DOCNO>
	<brief_summary>We study investigational drug call intranasal oxytocin ( Syntocinon® ) . Syntocinon® approve U.S. Food Drug Administration use help woman breastfeed , approve use child ASD . However , previous research conduct indicated administration oxytocin , adult ASD demonstrate improvement social cognition , reduce repetitive behaviour anxiety . There also early research suggest child may also benefit area . The purpose study test oxytocin work help child adolescent ASD .</brief_summary>
	<brief_title>Intranasal Oxytocin Treatment Children Adolescents With Autism Spectrum Disorders ( ASD )</brief_title>
	<detailed_description>Extensive data accumulate suggest central release oxytocin important social cognition function , well likely involved anxiety modulation repetitive behavior . The Principal Investigator Co-Principal Investigator study previously document : 1 ) association ASD single nuclear polymorphism oxytocin receptor gene , 2 ) ability measure oxytocin level blood enzyme immunoassay 3 ) preliminary data support safety efficacy intranasal oxytocin treatment social deficit repetitive behavior adult autism . A medication treatment target core deficit ASD childhood highly valuable could influence developmental trajectory make psychosocial intervention possible . In context , propose randomize placebo control trial intranasal oxytocin child adolescent ASD .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female outpatient , 1017 year age inclusive . 2 . Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition . Diagnostic Statistical Manual ( DSMIV ) criterion establish clinician expertise individual ASD . Best estimate Diagnosis reach use DSMIV criterion , Autism Diagnostic Observation Schedule ( ADOS2 ) Autism Diagnostic Interview ( ADIR ) . 3 . Have Clinician 's Global ImpressionSeverity ( CGIS ) score ≥ 4 ( moderately ill ) Screening . 4 . Verbal performance scale Intelligence Quotient ( IQ ) ≥ 70 ( subtests Wechsler Abbreviated Scale Intelligence ( WASII WASIII ≥ 70 ) . 5 . If already receive stable concomitant medication affect behavior , continuous participation 1 month prior Screening ( exception fluoxetine , period 6 week need ) , electively initiate new modify ongoing medication duration study . 6 . If already receive stable nonpharmacologic educational , behavioral , and/or dietary intervention , continuous participation precede 3 month prior Screening , electively initiate new modify ongoing intervention duration study . 7 . Have normal physical examination laboratory test result Screening . If abnormal , find ( ) must deem clinically significant Treating Clinician . 8 . Ability speak understand English sufficiently allow completion study assessment . 9 . Ability obtain write informed consent participant , developmentally appropriate . If participant capacity consent , ability obtain assent ( developmentally appropriate ) , well write inform consent parent ( ) /legal guardian . Exclusion Criteria 1 . Patients born prior 35 week gestational age . 2 . Patients primary psychiatric diagnosis ASD . 3 . Patients medical history neurological disease , include , limited , epilepsy/seizure disorder ( except simple febrile seizure ) , movement disorder , tuberous sclerosis , fragile X , know genetic syndrome , know abnormal brain MRI/structural lesion . 4 . Pregnant female patient , sexually active female patient hormonal birth control sexually active female use least two type nonhormonal birth control . 5 . Patients evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease . 6 . Patients one following : HIV , Hepatitis B virus , Hepatitis C virus , hemophilia ( bleed problem , recent nose brain injury ) , abnormal blood pressure ( hypotension hypertension ) , drug abuse , immunity disorder severe depression . 7 . Patients currently take oxytocin take intranasal oxytocin past response . 8 . Patients sensitivity oxytocin component formulation . 9 . Patients unable tolerate venipuncture procedure blood sample . 10 . Patients foster care province/state define legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism</keyword>
	<keyword>Social</keyword>
	<keyword>Functioning</keyword>
	<keyword>Cognition</keyword>
	<keyword>Repetitive Behaviors</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Quality Life</keyword>
</DOC>